ArticlePloS one2025
The effectiveness and safety of continuous and repeated treatment of atosiban in twin pregnancy with threatened preterm labor: A propensity score-matched study.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis retrospective cohort study aimed to evaluate the effects and adverse outcomes of continuous and repeated treatment with atosiban in twin pregnancies with threatened preterm labor. PATIENTS AND
methodsThe study was conducted at the Department of Obstetrics, Obstetrics and Gynecology, Hospital of Fudan University and included 90 twin pregnancies diagnosed with threatened preterm labor between January 2018 and December 2022. The pregnancies received atosiban tocolytic treatment. The data was divided into two groups based on whether continuous and repeated treatment was administered. Delivery outcomes, as well as maternal and neonatal complications, were analyzed. Propensity score matching (PSM) was employed to create comparable groups.
resultsOut of the 90 women, 34 received continuous and repeated treatment, while 56 did not. After PSM, 33 women who received continuous and repeated treatment were matched with 33 women who did not. The continuous and repeated treatment group showed a significant prolongation of pregnancy (p = 0.001) with a hazard ratio of 0.58 (95%CI, 0.35-0.96), and a later gestational age (p = 0.042). These patients also had a more complete cycle of antenatal steroids (p = 0.002) and a lower proportion of cases requiring operative delivery due to fetal distress (OR=0.14 [0.03-0.75], p = 0.004). Additionally, neonates in the continuous and repeated treatment group had a lower rate of admission to the neonatal intensive care unit (NICU) (OR=0.41 [0.19-0.89], p = 0.023).
conclusionThis propensity score-matched study suggests that continuous and repeated treatment with atosiban may effectively prolong pregnancy in cases of twin pregnancies with threatened preterm labor. Continuous and repeated treatment with atosiban was associated with lower fetal distress and lower NICU admission but no effect in adverse neonatal outcomes as well as the incidence of chorioamnionitis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.